Navigation Links
Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Date:8/19/2010

LONDON, Aug. 19 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

Quark is currently conducting a Phase II clinical trial of QPI-1002 for the prevention of acute kidney injury in patients undergoing cardiac surgery and for delayed graft function in kidney transplant patients.  Based on the announcement issued by Quark on 18 August 2010, and under the terms of Silence's agreement with Quark, Silence anticipates that its future milestone payments from this program could potentially exceed $65 million.    

Commenting on today's announcement, Phil Haworth, CEO of Silence, said: "We are delighted that Novartis has chosen to take this development option for QPI-1002.  This serves as further validation of Silence's leading AtuRNAi technology and we look forward to receiving the significant milestones as the development of QPI-1002 continues."

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a libra
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
10. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
11. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... CA (PRWEB) , ... August 28, 2015 , ... ... in Personalized Medicine, presented two studies at the International Spine Intervention Society’ ... July 28th, 2015 through to August 1st, 2015. With a focus on evidence-based ...
(Date:8/28/2015)... ... August 28, 2015 , ... Riordan-McKenna Institute ... DO, announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed ... an otherwise non-healing surgical knee wound. , The case involved a 78-year-old male, ...
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , a ... is pleased to announce their ranking as one of the top 5000 companies listed ... private companies across the nation. , “It is truly an honor to be recognized ...
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... after the NASDAQ Global Market closes on Monday, May 11, ... Executive Officer, and Robert E. Hoffman, Arena,s Vice President, Finance ... 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss ...
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... a part of its restructuring program to focus the ... leads. Following these reductions, Neurocrine will have approximately ... this painful decision that will have such an effect ...
... Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ), a ... candidates principally for use in the hospital setting, announced today ... a corporate overview at the following investment conferences: , ... Bank of America Merrill Lynch 2009 Healthcare Conference at the ...
Cached Biology Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009 3Neurocrine Announces Work Force Restructuring 2Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009 2
(Date:8/25/2015)... and BELLEVUE, Wash. , ... in advanced robotic systems, announced today it will unveil ... ground vehicle (UGV), at the National Tactical Officers Association ... The Guardian S is the first-ever commercially ... of years of research and in-field trials and is ...
(Date:8/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... The Smart Card Alliance and the EMV Migration Forum.  ... the Smart Card Alliance Latin America (SCALA) Chapter provides ... and thought leaders promoting adoption of smart card technology. ...
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... Center researchers reveals how a well-known tumor suppressor gene may ... published online today in Oncogene , focus on the ... who have hereditary breast and/or ovarian cancers, according to senior ... of Human Science at the School of Nursing & Health ...
... dementia and while some risks are known, for example ... clear. New research published in BioMed Central,s open access ... hospitalization and treatment in the intensive care unit (ICU) ... such as delirium, or acute dialysis are all independently ...
... small-scale polar storms could make a big difference to climate ... Anglia and the University of Massachusetts. Difficult-to-forecast polar ... are missing in most climate models. Research published ... could paint a different picture of climate change in years ...
Cached Biology News:Study uncovers mechanism used by BRCA1 to suppress tumors 2Worries about dementia how hospitalization affects the elderly 2'Missing' polar weather systems could impact climate predictions 2
High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
... cDNA sequencing and finishing services are ... can perform large-scale 5' screening or ... Our considerable experience with large-scale genome ... Agencourt an ideal cDNA outsourcing solution. ...
GLP-compliant, CLIA-certified DNA sequencing service. ASQ and SQA certified quality assurance staff. Auditors welcome....
A component of the Acridinium protein labeling kit....
Biology Products: